国家卫生与临床优化研究所（NICE）每质量调整生命年（QALY）的成本阈值范围应该提高吗？不应该。 - Suppr

Suppr

超能文献

Should NICE's threshold range for cost per QALY be raised? No.

作者信息

Raftery James

机构信息

University of Southampton, Southampton SO16 7PX.

出版信息

BMJ. 2009 Jan 26;338:b185. doi: 10.1136/bmj.b185.

DOI:10.1136/bmj.b185

PMID:19171562

Abstract

摘要

相似文献

Should NICE's threshold range for cost per QALY be raised? No.

BMJ. 2009 Jan 26;338:b185. doi: 10.1136/bmj.b185.

Should NICE's threshold range for cost per QALY be raised? Yes.

BMJ. 2009 Jan 26;338:b181. doi: 10.1136/bmj.b181.

How NICE may be outflanked.

BMJ. 2006 May 27;332(7552):1268-71. doi: 10.1136/bmj.332.7552.1268.

Crossing the line: NICE's value for money threshold.

BMJ. 2016 Mar 9;352:i1336. doi: 10.1136/bmj.i1336.

Review of NICE's recommendations, 1999-2005.

BMJ. 2006 May 27;332(7552):1266-8. doi: 10.1136/bmj.332.7552.1266.

How to pick a prescription.

Health Serv J. 2008 Mar 13:28-9.

Value based pricing for NHS drugs: an opportunity not to be missed?

BMJ. 2008 Feb 2;336(7638):251-4. doi: 10.1136/bmj.39434.500185.25.

Some inconsistencies in NICE's consideration of social values.

Pharmacoeconomics. 2014 Nov;32(11):1043-53. doi: 10.1007/s40273-014-0204-4.

Data briefing. The NICE threshold.

Health Serv J. 2007 Sep 20;117(6074):21.

Government pushes ahead with plan for cheaper drugs deal for NHS.

BMJ. 2007 Aug 11;335(7614):273. doi: 10.1136/bmj.39300.405822.DB.

引用本文的文献

Is Economic Evaluation and Care Commissioning Focused on Achieving the Same Outcomes? Resource-Allocation Considerations and Challenges Using England as a Case Study.

Appl Health Econ Health Policy. 2024 Jul;22(4):435-445. doi: 10.1007/s40258-024-00875-3. Epub 2024 Mar 11.

A rapid review of antenatal hepatitis C virus testing in the United Kingdom.

BMC Pregnancy Childbirth. 2023 Nov 28;23(1):823. doi: 10.1186/s12884-023-06127-x.

How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition's Lung Facts.

Appl Health Econ Health Policy. 2023 Jul;21(4):547-558. doi: 10.1007/s40258-023-00802-y. Epub 2023 Apr 11.

Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy.

Appl Health Econ Health Policy. 2022 Sep;20(5):651-667. doi: 10.1007/s40258-022-00730-3. Epub 2022 Jun 7.

Why Cancer?

Pharmacoeconomics. 2016 Jul;34(7):625-7. doi: 10.1007/s40273-016-0413-0.

Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population.

Patient Prefer Adherence. 2015 Dec 18;10:1-7. doi: 10.2147/PPA.S93760. eCollection 2016.

How much might a society spend on life-saving interventions at different ages while remaining cost-effective? A case study in a country with detailed data.

Popul Health Metr. 2015 Jul 8;13:15. doi: 10.1186/s12963-015-0052-2. eCollection 2015.

How much should the NHS pay for a QALY?

Pharmacoeconomics. 2013 May;31(5):357-9. doi: 10.1007/s40273-013-0062-5.

Cost-effectiveness acceptability curves revisited.

Pharmacoeconomics. 2013 Feb;31(2):93-100. doi: 10.1007/s40273-012-0011-8.

Cost-effectiveness of conservative treatments for neck pain: a systematic review on economic evaluations.

Eur Spine J. 2012 Aug;21(8):1441-50. doi: 10.1007/s00586-012-2272-5. Epub 2012 Mar 25.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Should NICE's threshold range for cost per QALY be raised? No.

BMJ. 2009 Jan 26;338:b185. doi: 10.1136/bmj.b185.

Should NICE's threshold range for cost per QALY be raised? Yes.

BMJ. 2009 Jan 26;338:b181. doi: 10.1136/bmj.b181.

How NICE may be outflanked.

BMJ. 2006 May 27;332(7552):1268-71. doi: 10.1136/bmj.332.7552.1268.

Crossing the line: NICE's value for money threshold.

BMJ. 2016 Mar 9;352:i1336. doi: 10.1136/bmj.i1336.

Review of NICE's recommendations, 1999-2005.

BMJ. 2006 May 27;332(7552):1266-8. doi: 10.1136/bmj.332.7552.1266.

How to pick a prescription.

Health Serv J. 2008 Mar 13:28-9.

Value based pricing for NHS drugs: an opportunity not to be missed?

BMJ. 2008 Feb 2;336(7638):251-4. doi: 10.1136/bmj.39434.500185.25.

Some inconsistencies in NICE's consideration of social values.

Pharmacoeconomics. 2014 Nov;32(11):1043-53. doi: 10.1007/s40273-014-0204-4.

Data briefing. The NICE threshold.

Health Serv J. 2007 Sep 20;117(6074):21.

Government pushes ahead with plan for cheaper drugs deal for NHS.

BMJ. 2007 Aug 11;335(7614):273. doi: 10.1136/bmj.39300.405822.DB.

引用本文的文献

Is Economic Evaluation and Care Commissioning Focused on Achieving the Same Outcomes? Resource-Allocation Considerations and Challenges Using England as a Case Study.

Appl Health Econ Health Policy. 2024 Jul;22(4):435-445. doi: 10.1007/s40258-024-00875-3. Epub 2024 Mar 11.

A rapid review of antenatal hepatitis C virus testing in the United Kingdom.

BMC Pregnancy Childbirth. 2023 Nov 28;23(1):823. doi: 10.1186/s12884-023-06127-x.

How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition's Lung Facts.

Appl Health Econ Health Policy. 2023 Jul;21(4):547-558. doi: 10.1007/s40258-023-00802-y. Epub 2023 Apr 11.

Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy.

Appl Health Econ Health Policy. 2022 Sep;20(5):651-667. doi: 10.1007/s40258-022-00730-3. Epub 2022 Jun 7.

Why Cancer?

Pharmacoeconomics. 2016 Jul;34(7):625-7. doi: 10.1007/s40273-016-0413-0.

Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population.

Patient Prefer Adherence. 2015 Dec 18;10:1-7. doi: 10.2147/PPA.S93760. eCollection 2016.

How much might a society spend on life-saving interventions at different ages while remaining cost-effective? A case study in a country with detailed data.

Popul Health Metr. 2015 Jul 8;13:15. doi: 10.1186/s12963-015-0052-2. eCollection 2015.

How much should the NHS pay for a QALY?

Pharmacoeconomics. 2013 May;31(5):357-9. doi: 10.1007/s40273-013-0062-5.

Cost-effectiveness acceptability curves revisited.

Pharmacoeconomics. 2013 Feb;31(2):93-100. doi: 10.1007/s40273-012-0011-8.

Cost-effectiveness of conservative treatments for neck pain: a systematic review on economic evaluations.

Eur Spine J. 2012 Aug;21(8):1441-50. doi: 10.1007/s00586-012-2272-5. Epub 2012 Mar 25.